Interaction of engineered nanomaterials with the immune system: Health-related safety and possible benefits

Abstract Understanding the mechanisms of interaction between nanomaterials and the immune system will provide us with endless possibilities of exploiting nano-objects for tuning immune responses towards preventing or curing diseases. We propose here strategies and actions that could help us in strengthening and exploiting such knowledge. By varying their composition, size, shape, and surface properties, it is possible to obtain a vast range of nanocarriers to target specific organs, tissues or cells for diagnostic, preventive and therapeutic purposes. Also, evaluation of immunosafety of such nanomaterials will contribute to designing nanomedical products devoid of side effects. In this review, we will describe the interaction of nanoparticles with the systemic and tissue-specific immune system, with a particular focus on innate immunity, aiming at providing information on the state-of-the art of nano-immune interactions and perspectives about future possibilities of exploitation.

[1]  Kevin Kendall,et al.  Surfactant protein D (SP-D) alters cellular uptake of particles and nanoparticles , 2013, Nanotoxicology.

[2]  A. Judge,et al.  Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Max Costa,et al.  Genetic and Epigenetic Effects of Nanoparticles , 2013 .

[4]  Diana Boraschi,et al.  Modulation of Macrophage Activation , 2016 .

[5]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[6]  T. Ishida,et al.  Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Diana Boraschi,et al.  Induction of Innate Immune Memory by Engineered Nanoparticles: A Hypothesis That May Become True , 2017, Front. Immunol..

[8]  Luca Costantino,et al.  Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. , 2012, Nanomedicine.

[9]  J. McKearn,et al.  Biochemical and Immunological Properties of Cytokines Conjugated to Dendritic Polymers , 2004, Biomedical microdevices.

[10]  Marina A Dobrovolskaia,et al.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Albert Duschl,et al.  Nanoparticles and Allergy , 2014 .

[12]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  K. P. Murphy,et al.  Janeway's immunobiology , 2007 .

[14]  Paolo Decuzzi,et al.  Deformable Discoidal Polymeric Nanoconstructs for the Precise Delivery of Therapeutic and Imaging Agents. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  D. Fischer,et al.  Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  Wei Zhao,et al.  References Subscriptions Permissions Email Alerts Fullerene Nanomaterials Inhibit the Allergic Response , 2013 .

[17]  Lucia Migliore,et al.  Epigenetic effects of nano-sized materials. , 2013, Toxicology.

[18]  David Leong,et al.  Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. , 2007, Molecular pharmaceutics.

[19]  A. Casset,et al.  Immunomodulatory properties of multi-walled carbon nanotubes in peripheral blood mononuclear cells from healthy subjects and allergic patients. , 2013, Toxicology letters.

[20]  M. Pallardy,et al.  Why the Immune System Should Be Concerned by Nanomaterials? , 2017, Front. Immunol..

[21]  Samir Mitragotri,et al.  Role of target geometry in phagocytosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[23]  M. Netea,et al.  Adaptive Characteristics of Innate Immune Responses in Macrophages. , 2016, Microbiology spectrum.

[24]  D. Josephs,et al.  Tumour-associated macrophage polarisation and re-education with immunotherapy. , 2015, Frontiers in bioscience.

[25]  Michaela Kendall,et al.  Surfactant protein A (SP-A) inhibits agglomeration and macrophage uptake of toxic amine modified nanoparticles , 2015, Nanotoxicology.

[26]  Marina A Dobrovolskaia,et al.  Choice of method for endotoxin detection depends on nanoformulation. , 2014, Nanomedicine.

[27]  Abhinav Kumar,et al.  Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[28]  P Couvreur,et al.  In vitro evaluation of nanoparticles spleen capture. , 1999, Life sciences.

[29]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[30]  John Samuel,et al.  Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Bengt Fadeel,et al.  Extracellular entrapment and degradation of single-walled carbon nanotubes. , 2014, Nanoscale.

[32]  Bengt Fadeel,et al.  It takes two to tango: Understanding the interactions between engineered nanomaterials and the immune system. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[33]  Judith Klein-Seetharaman,et al.  Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. , 2010, Nature nanotechnology.

[34]  Mauro Ferrari,et al.  Nanogeometry: beyond drug delivery. , 2008, Nature nanotechnology.

[35]  Russell J Mumper,et al.  Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. , 2004, Vaccine.

[36]  Jean-Christophe Leroux,et al.  Effect of poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. , 2009, Biomacromolecules.

[37]  John Samuel,et al.  Biodegradable nanoparticle delivery of a Th2‐biased peptide for induction of Th1 immune responses , 2006, The Journal of pharmacy and pharmacology.

[38]  Elisa Boutet-Robinet,et al.  Food-grade TiO2 impairs intestinal and systemic immune homeostasis, initiates preneoplastic lesions and promotes aberrant crypt development in the rat colon , 2017, Scientific Reports.

[39]  Biana Godin,et al.  Macrophage Polarization Contributes to the Anti-Tumoral Efficacy of Mesoporous Nanovectors Loaded with Albumin-Bound Paclitaxel , 2017, Front. Immunol..

[40]  S. Krämer,et al.  Particle size and activation threshold: a new dimension of danger signaling. , 2010, Blood.

[41]  Denis Girard,et al.  Silver nanoparticles rapidly induce atypical human neutrophil cell death by a process involving inflammatory caspases and reactive oxygen species and induce neutrophil extracellular traps release upon cell adhesion. , 2015, International immunopharmacology.

[42]  Diana Boraschi,et al.  The Gracefully Aging Immune System , 2013, Science Translational Medicine.

[43]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. , 2014, Molecular immunology.

[44]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[45]  J. Tschopp,et al.  Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β , 2010, Proceedings of the National Academy of Sciences.

[46]  Bengt Fadeel,et al.  Nanoparticles and innate immunity: new perspectives on host defence. , 2017, Seminars in immunology.

[47]  Bengt Fadeel,et al.  Clear and present danger? Engineered nanoparticles and the immune system. , 2012, Swiss medical weekly.

[48]  N. Sheikh,et al.  Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses. , 1999, Vaccine.

[49]  Matthew Boyles,et al.  Nanoparticle-allergen interactions mediate human allergic responses: protein corona characterization and cellular responses , 2015, Particle and Fibre Toxicology.

[50]  H. Krug,et al.  Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants. , 2007, Toxicology letters.

[51]  G. Ott,et al.  Development of Vaccine Adjuvants: A Historical Perspective , 2006 .

[52]  Bengt Fadeel,et al.  Impaired Clearance and Enhanced Pulmonary Inflammatory/Fibrotic Response to Carbon Nanotubes in Myeloperoxidase-Deficient Mice , 2012, PloS one.

[53]  Richard A Flavell,et al.  Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. , 2009, Vaccine.

[54]  T. Miyakawa,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .

[55]  H. Merkle,et al.  Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[56]  M. Fraga,et al.  The effect of exposure to nanoparticles and nanomaterials on the mammalian epigenome , 2016, International journal of nanomedicine.

[57]  Per Axel Clausen,et al.  Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. , 2011, ACS nano.

[58]  P. Petersen,et al.  Endotoxins-the invisible companion in biomaterials research. , 2013, Tissue engineering. Part B, Reviews.

[59]  Albert Duschl,et al.  Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects , 2011, Particle and Fibre Toxicology.

[60]  Jürgen Groll,et al.  Phagocytosis independent extracellular nanoparticle clearance by human immune cells. , 2010, Nano letters.

[61]  John D. Lambris,et al.  Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine , 2011, The Journal of Immunology.

[62]  Chi-Feng Hung,et al.  The impact of cationic solid lipid nanoparticles on human neutrophil activation and formation of neutrophil extracellular traps (NETs). , 2015, Chemico-biological interactions.

[63]  I. Bellinghausen,et al.  Recent advances in the use of nanoparticles for allergen‐specific immunotherapy , 2017, Allergy.

[64]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[65]  Diana Boraschi,et al.  Optimising the use of commercial LAL assays for the analysis of endotoxin contamination in metal colloids and metal oxide nanoparticles , 2015, Nanotoxicology.

[66]  Miklós Tóth,et al.  Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles , 2007, Journal of liposome research.

[67]  R. Xavier,et al.  Trained immunity: A program of innate immune memory in health and disease , 2016, Science.

[68]  Zhenzhen Shi,et al.  Bacterial endotoxin (lipopolysaccharide) binds to the surface of gold nanoparticles, interferes with biocorona formation and induces human monocyte inflammatory activation , 2017, Nanotoxicology.

[69]  Scott E McNeil,et al.  Nanotechnology safety concerns revisited. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[70]  B. Erlanger,et al.  Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Diana Boraschi,et al.  From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology , 2015, Vaccines.

[72]  Marina A Dobrovolskaia,et al.  Evaluation of nanoparticle immunotoxicity. , 2009, Nature nanotechnology.

[73]  Judith Klein-Seetharaman,et al.  Biodegradation of single-walled carbon nanotubes by eosinophil peroxidase. , 2013, Small.

[74]  E. Latz,et al.  Activation and regulation of the inflammasomes , 2013, Nature Reviews Immunology.